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Abstract
The activity of pharmaceutical substances crucially depends on the bioavailability of the substances. The bioavailability of drugs 
in body and their rate of dissolution in the biological fluids are increased if the particle size is decreased. In the present paper, the 
Gas Anti-Solvent (GAS) method was used to lower the size of rosuvastatin particles. The effects of temperature (313–338 K), pressure 
(105–180 bar) and initial solute concentration (20–60 mg/ml) were evaluated by Response Surface Methodology (RSM). The optimum 
initial solute concentration, temperature and pressure were found to be 20 mg/ml, 313 K and 180 bar, respectively which resulted in 
the minimum particle size. Furthermore, the particles were characterized by Differential Scanning Calorimetry (DSC), Dynamic Light 
Scattering (DLS), Fourier Transform Infrared (FTIR) spectroscopy, scanning electron microscopy (SEM), and X-Ray Diffraction (XRD). 
The analyses showed that the rosuvastatin particles (60.3 nm) precipitated by GAS process become significantly smaller than the initial 
particles (45.8 µm).
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1 Introduction
In the pharmaceutics, the insolubility or weak solubility 
of many drugs in the biological media results in the lim-
ited bioavailability, and at the low doses, the therapeutic 
response is poor [1]. It has been estimated that more than 
60 % of pharmaceutical drugs have poor water solubility. 
A major challenge in the pharmaceutics is that the drugs are 
weakly soluble in water. The weak solubility of a drug may 
also lead to the low dissolution characteristics which may 
bring about limited bioavailability as well as reduced ther-
apeutic efficacy [2]. In addition, the size of drug particle 
is a limiting factor contributing to the low bioavailability 
of the compounds with the weak solubility. The more the 
surface area, the higher the interaction with a solvent, and 
as a result, the more the solubility [1, 2]. In the biological 
media, the dissolution rate of drugs can be improved using 
the micronization method to resolve the above problems.
There are several methods developed for improving 
the rate of dissolution in the drugs weakly soluble in the 
water, including the salt formation [3], surfactant-assisted 
solubilization [4, 5], particle size reduction [6, 7], micro 
emulsion [8], self-emulsification [9], rapid dissolving tab-
lets [10], complexation [11] and solid dispersion [12, 13]. 
Moreover, many conventional methods such as grinding, 
sieving, re-crystallization with evaporation of solvent, and 
milling spray drying, which can be employed for increasing 
the dissolution rate and reducing the particle size. During the 
mechanical treatment, the products may be degraded in the 
high temperatures and when subjected to the toxic solvents. 
It is however difficult to achieve the favorable size and distri-
bution of particles using the conventional methods [14, 15].
To transcend the disadvantages of traditional processes, 
the supercritical fluid technology can be utilized. Carbon 
dioxide is the most commonly used supercritical fluid, 
because it possesses the properties including the nontox-
icity, low critical pressure and temperature (73.8 bar and 
304.55 K), relatively high purity, low cost, chemical stability 
and non-inflammability [16–19]. The methods such as Rapid 
Expansion of Supercritical Solutions (RESS), anti-solvent 
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processes (Gas Anti-Solvent (GAS)), Supercritical Anti-
Solvent (SAS), Aerosol Solvent Extraction System (ASES), 
Solution Enhanced Dispersion (SEDS) by supercritical flu-
ids and Particles from Gas-Saturated Solutions/Suspensions 
(PGSS) use supercritical fluids to make fine particles [14, 15, 
20–23]. The GAS technique has been used to obtain the 
particles of submicron sizes in a variety of drugs including 
the aspirin [24], ampicillin [18, 25], 5-Fluorouracil [19, 26] 
and phenanthrene [27].
In the developed countries, the fatalities are primarily 
caused by Coronary Heart Disease (CHD), and hyperlipid-
emia is a major risk factor which can be modified to CHD. 
In the clinical trials, it has been found that the risk of car-
diovascular deaths can be lowered with the decrease in the 
plasma cholesterol. ROSCa, whose commercial name is 
Crestor, is a member of a group of drugs known as statins 
or HMG-CoA reductase which is chemically known as 
3-hydroxy-3-methylglutaryl-coenzyme A. This drug is 
commonly used to treat hyperlipidemia [28]. As the first 
phase in the biosynthesis of cholesterol, this enzyme is used 
for the catalysis of the HMG-CoA conversion to meva-
lonate. Furthermore, ROSCa has been employed to reduce 
bad cholesterol (such as TG and LDL) and to enhance the 
good cholesterol (HDL) of the blood [29]. It has been used 
as a synthetic drug to lower the lipid and to treat the dis-
eases such as benign prostatic hyperplasia, osteoporosis, 
atherosclerosis, triglyceridemia, dyslipidemia, familial 
hyperlipidemia and Alzheimer's disease [29].
Based on the biopharmaceutical classification, ROSCa 
is a member of class 2 (low solubility-high permeability) 
drugs due to its crystalline nature [29, 30]. It is slightly 
soluble in water and has low oral bioavailability of about 
20 % [31]. In addition, ROSCa has a weak solubility in 
supercritical carbon dioxide (molar fraction solubility 
3.00 × 10−6 to 2.44 × 10−4 at pressure of 121.6–354.6 bar 
and temperature of 308–348 K) [32]. The mole fraction 
of crystalline ROSCa is soluble in water ranging from 
5.40 × 10−6 to 1.40 × 10−5 at atmospheric pressure and tem-
peratures of 298.15–318.15 K [33].
To the best of authors' knowledge, the formation of 
ROSCa nanoparticles by GAS has not yet been studied in 
literature. The purpose of this research is hence to produce 
ROSCa nanoparticles to increase their dissolution rate. 
In this study, the Response Surface Methodology (RSM) 
was applied along with the Central Composite Design 
(CCD) to describe the optimum conditions for reducing the 
particle size. The effect of different parameters (initial con-
centration of solute, temperature and pressure) on the size of 
ROSCa particles was investigated. Furthermore, the Fourier 
Transform Infrared spectroscopy (FTIR) analysis, X-Ray 
Diffraction (XRD), Differential Scanning Calorimetry 
(DSC), and Scanning Electron Microscopy (SEM) were 
used to characterize the products and raw materials.
2 Materials and methods
2.1 Materials
Rosuvastatin calcium (CAS Number 147098-20-2) as solid 
drug with 98.7 % purity was obtained from Alborz Bulk 
Pharmaceutical Company (Tehran, Iran). The applied sol-
ute was dimethyl sulfoxide (DMSO) with CAS Number 
of 67-68-5 and purity of 99.9 %, Sigma-Aldrich chemi-
cals which was employed without any further purifica-
tion. Carbon dioxide ( CO2 ) with 99.998 % purity and CAS 
Number of 124-38-9 was prepared from Abughaddareh 
Company (Shiraz, Iran). The molecular structure of 
ROSCa used in this study are listed in Fig. 1. 
2.2 Methods
2.2.1 Experimental procedure
GAS process was used to recrystallize the solid compounds 
that are not dissolved in a supercritical fluid. In GAS pro-
cess, the dissolution of solute is done in a liquid organic 
solvent using a gas as an antisolvent for the solute. The gas-
eous antisolvent can be CO2 . The CO2 dissolves into the 
liquid solution and causes volume expansion. Because of 
the antisolvent property of dissolved CO2 , the solute is pre-
cipitated from the solution. In order to achieve a homoge-
neous distribution of antisolvent in the liquid solution, the 
SC-CO2 is rapidly inserted to the solution to close the pres-
sure chamber. According to the volume of cell (100 ml), by 
increasing the gas concentration in solution and expanding 
the solution volume, the particle is precipitated. The tem-
perature, pressure and initial concentration of solute are 
effective parameters on the reduction of particles size. 
These parameters can control the particle size distribution 
of the product and the particles with narrower size distribu-
tion can be produced [25, 33, 34].
Fig. 1 Molecular structure of ROSCa
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As can be observed in Fig. 2, the system contains 
gas cylinders, filter, refrigerator, pump (Haskel), oven 
(Memert), cell, back pressure (Drasstar), micrometer valve 
(Swagelok), sampler. In this work, ROSCa was initially dis-
solved in different concentration (between 20–60 mg/ml) 
in an organic solvent (DMSO) in a glass vial. This solution 
was placed in the precipitation cell and the precipitator 
temperature was then raised until the experimental tem-
perature. A high-pressure pump was used to pressurize 
the carbon dioxide to the required pressure. After reach-
ing the experimental temperature and pressure, the pump 
was turned off and the solution was stored in the precip-
itator until the saturation of supercritical CO2 with ROS 
for 30 min. The particles were precipitated in sinter metal 
filter. The DMSO was removed from the particles at a con-
stant flow rate (3 g/min) of CO2 for 60 min. Finally, the sys-
tem was depressurized and the sample was filter-collected, 
and stored for further analysis. Particles were found to be 
dry in all reported cases [33]. The process parameters and 
levels are presented in Table 1. 
2.2.2 Particle characterization
In this study, characterization tests for ROSCa nanopar-
ticles included the Dynamic Light Scattering (DLS), 
Scanning Electron Microscopy (SEM), Differential 
Scanning Calorimetry (DSC), Fourier Transform Infrared 
(FTIR) spectroscopy, and X-Ray Diffraction (XRD).
Scanning Electron Microscopy (SEM)
SEM (TESCAN, VEGA 3, Czech Republic) was con-
ducted for the both processed and unprocessed ROSCa 
particles to explore the size distribution, average particle 
size, and particle morphology. The particles were con-
nected on top of the SEM aluminum stubs to the carbon 
tape for the analysis, and then, using the sputter coater, 
they were coated with gold.
X-Ray Diffraction (XRD)
To analyze the ROSCa crystallinity, XRD (XRD; Philips 
X'pert Pro MPD) was conducted for 2θ = 10–80° and 
1 deg/min scanning rate using the copper anode as a radi-
ation source (k = 1.54 Å).
Fourier Transform Infrared spectroscopy (FTIR)
The potassium bromide pellet technique was used to 
record the FTIR spectra of ROS by FTIR (Perkin Elmer, 
RX1, Germany) for the 400–4000 cm−1 wavenumber 
at room temperature.
Differential Scanning Calorimetry (DSC)
For thermal analysis, DSC (DSC, 404 F3 Pegasus from 
Netzsch; Germany) was done using 7 mg of the sample 
placed in an aluminum pan, which was sealed using a ref-
erence sealed empty pan. The samples were heated with the 
10 K/min scanning rate at 298.15–523.15 K temperature. 
Dynamic Light Scattering (DLS)
The measurement of hydrodynamic diameter of particles 
was done using the DLS (NANOPHOX; Sympatec GmbH 
System-Partikel-Technik) and was validated by compar-
ing to the particle size obtained from the SEM images. 
The analysis was performed after dissolving 5 mg of ROS 
in 1 ml of deionized water.
2.2.3 Experimental design (CCD) for nanoparticles 
production via GAS
The Response Surface Methodology (RSM) is used along 
with the Central Composite Design (CCD) as a statisti-
cal and mathematical technique to obtain the optimum 
conditions for determining the particle size as small as 
possible. This method is widely used in supercritical pro-
cesses [35–42]. The CCD was employed in this paper for 
each of the three independent variables in five levels and 
Table 1 Variable and their levels used to Central Composite 
experimental design.
Parameters Level 1 Level 2 Level 3 Level 4 Level 5




20 28 40 52 60
Temperature (K); x3 313 318 326 333 338
Fig. 2 Process flow diagram of experimental apparatus for Gas method.
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six axial points (with ±1.68 axial distance for orthogonal 
design) with six replicates in center points to study the 
impact of process factors on the morphology and size of 
the precipitated ROSCa particles.
Based on a CCD where the parameters were coded 
in five levels, namely −α, −1, 0, +1 and +α, as presented 
on Table 2. A total of N = 2k + 2k + 6 experiments were 
obtained for the four parameters, where k is the num-
ber of parameters (k = 3), i.e., the entire design involved 
20 experimental runs with six center points, eight factorial 
points (8), eight axial points (2 × 3) and six replicated cen-
ter points, according to CCD [35–38].
The independent variables were x1 , x2 and x3 represent-
ing pressure; initial solute concentration and temperature, 
respectively. The DLS was used to obtain the mean parti-
cle size ( x50 ). The system behavior can be expressed by a 
second-order polynomial equation [43, 44]:
Y x x x x x x
x x x x
= + + + + + +
+ + +
β β β β β β β
β β β






12 1 2 13 1 3 23 2 3
x x +ε ,
 (1)
where Y denotes the predicted response, x1 , x2 and x3 are the 
input variables; β0 is constant; β1 , β2 and β3 are the liner coef-
ficients; β11 , β22 and β33 are the quadratic coefficients; β12 , β13 
and β23 represent interaction coefficients and ε denotes the 
noise or error [45, 46]. The Design-Expert software (ver-
sion 7.0.0, Stat-Ease Inc., Minneapolis, USA) was used for 
the analysis of variance (ANOVA), including ( R2 ), adjusted 
R2, predicted R2 and F-values and for the regression and the 
graphical representation of obtained data.
Statistical testing of the model was performed with 
Fisher test to obtain the mathematical relationship between 
input and output parameters. To examine the goodness of 
fit of the model, a test for significance of regression model 
was performed and ANOVA is applied to the response 
data and the value p < 0.05 is considered as significant. 
The determination coefficients, R2, and their adjusted 
value, R2 adj., were used to evaluate the fit adequacy of the 
regression model [39–42].
3 Results and discussion
As shown in Table 2, twenty experiments were conducted 
to study the impact of temperature, pressure and initial 
concentration of solute on the size and distribution of 
ROSCa particles obtained from GAS process using the 
CCD statistical model. The level of independent variables 
used in this experiment was determined based on prelim-
inary experiments. The original particles had an irregular 
shape with the 45.8 µm average diameter. The experiment 
results are shown in Table 2.
3.1 Central composite experimental design and 
evaluation of the fitted model
To explore the effect of parameters on the size and dis-
tribution of particles, the experiments were carried out 
at five different operating pressures (10.5, 12, 14.3, 16.5 
and 18 MPa), temperatures (313, 318, 326, 338 and 338 K) 
and initial solute concentrations (40, 45, 53, 60, and 
65 mg/ml). The CCD method was used to determine the 
optimal conditions and choose the parameters with the 
highest impact on the morphology and size of the precip-
itated ROSCa particles in the GAS process. The Central 
Composite Design (CCD) was also used to investigate 
the parameters affecting the size and morphology of 
the precipitation particles by choosing three parameters 
and five levels. Table 1 presents the parameters and lev-
els. The structure of CCD design and the experimental 
results are shown in Table 2, Eq. (2) obtained from the 
RSM indicates the empirical relationship of the response 
to the independent variables (in coded units): 
Y x x x x
x x
= − + + +
+ − −
100 03 29 81 17 26 4 88 3 17
5 79 3 02 6






. . . . .
. . .47 2 82 1 68
1 2 1 3 2 3
x x x x x x− +. . ,
 (2)
Table 2 The independent variables for GAS process along with 












1 105 40 326 156.4 ± 9.8 159.14
2 143 20 326 90.4 ± 5.8 87.37
3 143 40 326 95.6 ± 7.4 100.03
4 120 52 333 167.8 ± 6.2 168.90
5 165 28 333 59.8 ± 7.3 65.75
6 143 40 338 103.9 ± 11.9 99.70
7 143 40 326 97.3 ± 5.9 100.03
8 180 40 326 65.7 ± 6.8 58.86
9 120 52 318 153.2 ± 12.5 150.15
10 143 40 326 100.5 ± 11.3 100.03
11 165 28 318 63.2 ± 4.8 65.00
12 143 40 326 102.1 ± 8.7 100.03
13 120 28 318 105.9 ± 5.1 106.02
14 143 60 326 146.5 ± 7.3 145.43
15 143 40 326 103.2 ± 6.5 100.03
16 143 40 313 83.2 ± 8.3 83.30
17 143 40 326 100.8 ± 11.9 100.03
18 165 52 318 79.9 ± 6.4 83.22
19 120 28 333 118.5 ± 10.4 118.08
20 165 52 333 87.9 ± 8.8 90.68
Temperature and Pressure uncertainties were 0.1 K and 1 bar.
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where Y represents the response (ROSCa particle size) and 
x1 , x2 and x3 are the coded values of the test (pressure, 
initial solute concentration and temperature, respectively). 
The response ranged from 60.3 to 168.9 nm. The analysis 
of variance (ANOVA) is presented in Table 3. The F-value 
and P-(prob) value were used to determine the signifi-
cance of each coefficient. The "Prob > F" values lower 
than 0.05 represent the significance of model terms. 
The model was found to be significant for the F-value 
of 630.36 (p < 0.0001). From the ANOVA results, pres-
sure ( x1 ) solute concentration ( x2 ) and temperature ( x3 ) 
were found to have the most significant impacts on the 
model. The R2 (R-square), adjusted R2 and predicted R2 
values were used to check the degree of fit for the qua-
dratic model. In fact, the more the R2 and adjusted R2 val-
ues, the better the proposed model will be fitted to the 
experimental data. The values of regression coefficient 
( R2 ) and adjusted determination coefficient (R2adj) of 
the model were 0.9893 and 0.9796, respectively. R2 and 
R2adj represent the goodness of fit for the experimental 
data. The three-dimensional response surface plots as the 
graphical representation of the regression equations are 
presented in Fig. 3 (a)–(c).
3.2 Effect of operating conditions on particle size
3.2.1 Effect of pressure
The influence of pressure on the mean particle size and 
its distribution was investigated at five levels (105, 120, 
Table 3 Analysis of variance (ANOVA) for quadratic model.
Source Sum of squares
Mean 
square F-value Prob > F
Intercept
x1 12137.63 12137.63 630.36 <0.0001
x2 4069.56 4069.56 211.35 <0.0001
x3 324.91 324.91 16.87 0.0021
x1x2 335.40 335.40 17.42 0.0019
x1x3 63.84 63.84 3.32 0.0986
x2x3 22.44 22.44 1.17 0.3056
x
1
2 144.85 144.85 7.52 0.0207
x2
2 482.56 482.56 25.06 0.0005
x
3
2 131.16 131.16 6.81 0.0260
Model 17749.23 1972.14 102.42 <0.0001
Residual 192.55 19.25
Lack of fit 150.40 30.08 3.57 0.0945








1218.49 0.9796 0.9321 35.50
Fig. 3 The 3D-plots (a) the influence of temperature and pressure on 
particle size at 40 mg/ml, (b) the influence of solute concentration 
and pressure on particle size at 326 K and (c) the influence of solute 
concentration and temperature on particle size at 114.3 bar
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143, 165 and 180 bar). Fig. 3 and Table 2 show that pres-
sure increase in constant temperature (313 K) from 105 to 
180 bar reduced the average particle size of ROSCa from 
135.8 to 80.3 nm. By elevation of the pressure, carbon 
dioxide density increased resulting in decline of the inter-
molecular mean distance of CO2 molecules. Therefore, 
the solubility of ROS in SC-CO2 was increased, result-
ing in the greater super-saturation, volume expansion and 
rate of nucleation. Therefore, an increase in the pressure 
may result in prevailing of nucleation mechanism and 
smaller particles of ROSCa. A similar result was achieved 
by Esfandiari and Ghoreishi [25, 34], Jafari et al. [24] and 
Chen et al. [47] for 5-Fluorouracil, ampicillin, aspirin and 
ginkgo ginkgolides, respectively. 
3.2.2 Effect of temperature
Owing to the effects on the solubility, super-saturation, 
and nucleation, temperature is an important parameter 
in the GAS process. Most of the researchers considered 
the effect of temperature in GAS process, Esfandiari and 
Ghoreishi [19, 25, 34], Müller et al. [48], Bakhbakhi et al. 
[27, 49] and Kim et al. [50] to name a few. Therefore, the 
experiments were conducted at different temperatures 
within the range of 313–338 K to assess the effect of tem-
perature on the size and distribution of ROSCa particles. 
Fig. 3 and Table 2, show that particle size was increased 
by temperature rise ranging 313–338 K. By increas-
ing the operating temperature, the ROSCa mean parti-
cle size appeared to be large. Particle precipitation with 
GAS process can be explained by the expansion of volume 
and decrease of solubility. The solubility of many drugs 
increases in organic solvent upon the temperature increase. 
In GAS process, volumetric expansion decreased by the 
temperature increment. Therefore, saturation and critical 
super-saturation lines sowed an upward shift. The domi-
nant mechanism is growth and the higher temperature led 
to higher ROSCa particle size.
3.2.3 Effect of initial solute concentration
The initial concentration of solute was found to be 
an effective factor for controlling the particle size in the 
GAS process. Therefore, the influence of initial solute 
concentration was addressed at five levels (20, 28, 40, 52 
and 60 mg/ml). The results of mean particle size analysis 
at different concentrations are shown in Fig. 3 and Table 2. 
If the initial concentration of ROSCa in the solution 
(DMSO) is reduced, the average size of particles exhibits 
a decrease. At high concentrations, a larger mean particle 
diameter was found, and for the lower volume expansion, 
the nucleation was achieved. Hence, the nucleuses were 
allowed to grow in a longer period. On the other hand, 
with decreasing the solute concentrations, solute precip-
itation occurred at higher volume expansion giving rise 
to smaller particles. Chen et al. [47], Esfandiari et al. [25] 
Jafari et al. [24] and Bakhbakhi et al. [49] obtained similar 
results about the impact of solute concentration on the size 
distribution and mean particle size of GAS process.
3.3 Optimum conditions
The CCD method was used to determine the optimum con-
dition for achieving the smallest particle size by implement-
ing in Design Expert 7.0 software. The determined values 
were as follows: initial concentration of solute: 20 mg/ml, 
temperature: 313 K and pressure: 180 bar. These values were 
predicted to result in particle size of 60.5 nm. The CCD 
method was utilized to evaluate the accuracy and validity of 
the optimization method through the experiments. As such, 
the average size of particles was 58.6 nm, which was very 
near to the value obtained from the estimation.
3.4 Solid state characterization
According to the FTIR analysis, the GAS process did 
not influence the ROSCa chemical structure. According 
to Fig. 4, the FTIR spectra were overlapped for the orig-
inal and the processed particles, reflecting that there is 
not any degradable compound in the structure of the pro-
cessed particles. The FTIR spectra were recorded for the 
wavenumber ranging from 400 to 4000 cm−1. IR spec-
trum of ROSCa showed the characteristic peaks at 3337.9, 
2968.23, and 1435.48 cm−1 corresponding to the cyclic 
amines, C-H stretching, C=O stretching, and O-H bend-
ing, respectively. A number of researchers reported the 
same results in their works [29, 51]. 
XRD is one of the most important analyses for explor-
ing the crystalline characteristics of raw materials, 
nanoparticles and physical mixture. X-ray diffractograms 
were taken to determine the structural nature of ROSCa 
(crystalline or amorphous). X-Ray Diffraction pattern of 
ROSCa in Fig. 5 (a)-(b) shows diffraction peaks at 2θ val-
ues. The absence of the characteristics peak in processed 
ROSCa compared to the original particles indicates the 
transition of the drug structure from crystalline to amor-
phous. Similar results were obtained by other research-
ers [16, 17, 52]. Nevertheless, the quite similar structures 
with the low peak intensities can be detected in the GAS-
processed particles as shown in Fig. 5 (b) (with the identi-
cal wavelength and diffraction angles). The reduced inten-
sities reflect the decrease in the crystallinity. 
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The SEM images displayed in Fig. 6 show the signif-
icant reduction in size as a morphological modification 
of the GAS-processed particles. Note that the shape of 
original ROS was irregular (see Fig. 6). On the contrary, 
as illustrated in Fig. 6, the quasi-spherical particles and 
appropriate Particle Size Distribution (PSD) were gen-
erated by the GAS process. PSD of the drug may have 
remarkable effects on drug product performance (e.g., dis-
solution, bioavailability, content uniformity, stability, etc.). 
Many researchers have confirmed that the PSDs of phar-
maceutical powders have profound influence on almost 
every step of manufacturing processes for solid oral dos-
age forms, including mixing, granulation, drying, milling, 
blending, coating, encapsulation, and compression [53, 54]. 
The SEM images of the original and processed particles 
were verified through the DLS analysis (Fig. 7). According 
to the DLS results, the nanoparticle size distribution ranged 
from 60.3 to 168.9 nm, which was more limited than that 
of the original ROS with the 45.8 μm mean. Furthermore, 
Differential Scanning Calorimetry (DSC) was employed 
as a supplementary measurement of XRD to characterize 
the thermal properties of materials. As illustrated in Fig. 8, 
the melting point of pure ROSCa is 432.05 K whereas GAS-
processed ROSCa has melting point of 427.35 K showing 
4.7 K deviation. Furthermore, decrease in melting enthalpy 
of DSC in the processed ROSCa particle could be due to 
changes in crystalline structure and reduction of the parti-
cle size. Therefore, it can be suggested that the crystalline 
nanoparticles were decreased. Several researchers reported 
similar results in [29, 55, 56].
4 Conclusion
This paper investigated the size and size distribution of 
GAS-processed ROSCa particles. The impact of process 
parameters including the temperature, pressure and ini-
tial concentration of solute on the ROSCa particles were 
Fig. 4 Comparison of the FTIR spectrum of original (Black) and GAS processed ROSCa (Blue)
Fig. 5 XRD patterns of ROSCa before and after the processes: 
(a) original, (b) GAS processed.
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Fig. 6 SEM images for various cases (based on Table 2): (a) the original  ROSCa, (b) Run 6, (c), Run 12, (d) Run19, (e) R-Optimum
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evaluated. Mean size of ROSCa particles was reduced from 
45.8 µm to 60.3 nm using the GAS method. The Response 
Surface Methodology (RSM) was successfully used to 
optimize the particle size. The optimal values of variables 
(temperature of 313 K, pressure of 180 bar and initial sol-
ute concentration of 20 mg/ml) could result in the small-
est particles. It was concluded that use of GAS process 
can decrease the size of ROSCa particles to nanoscale 
(60.3 nm). The particle size of ROSCa increased with 
the rise of initial concentration of solute and tempera-
ture. However, pressure increment decreased the ROSCa 
particles size. Furthermore, the original and precipitated 
ROSCa particles were analyzed with the SEM, DLS, DSC, 
XRD, and FTIR. The GAS-precipitated particles had an 
approximately spherical shape, whereas the unprocessed 
particles showed irregular forms.
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